Table 4.
Number of new active substances with an expedited review and therapeutically innovative rating
| Year | Number (%) of NAS with a therapeutic assessment from Patented Medicine Prices Review Board and/or Prescrire | Number of NAS with an expedited review | Number of NAS rated as therapeutic innovation by either Patented Medicine Prices Review Board and/or Prescrire | Number of therapeutically innovative NAS with an expedited review |
| 1995 | 22 (73.3) | 3 | 1 | 0 |
| 1996 | 20 (60.6) | 5 | 4 | 3 |
| 1997 | 24 (57.1) | 4 | 4 | 2 |
| 1998 | 24 (80.0) | 4 | 1 | 0 |
| 1999 | 31 (86.1) | 10 | 1 | 0 |
| 2000 | 20 (76.9) | 9 | 4 | 4 |
| 2001 | 23 (85.2) | 8 | 1 | 1 |
| 2002 | 20 (83.3) | 4 | 0 | 0 |
| 2003 | 19 (95.0) | 8 | 2 | 2 |
| 2004 | 26 (89.7) | 9 | 3 | 3 |
| 2005 | 21 (87.5) | 9 | 3 | 2 |
| 2006 | 21 (91.3) | 9 | 3 | 2 |
| 2007 | 22 (91.7) | 9 | 3 | 3 |
| 2008 | 15 (88.2) | 6 | 2 | 2 |
| 2009 | 26 (96.3) | 7 | 0 | 0 |
| 2010 | 19 (86.4) | 2 | 2 | 2 |
| 2011 | 23 (85.3) | 5 | 2 | 2 |
| 2012 | 21 (91.3) | 6 | 3 | 2 |
| 2013 | 36 (92.3) | 11 | 6 | 3 |
| 2014 | 22 (88.0) | 6 | 3 | 2 |
| 2015 | 30 (81.1) | 12 | 4 | 4 |
| 2016 | 24 (63.2) | 13 | 3 | 3 |
| 1995–2016 | 509 (81.7) | 159 | 55 | 42 |
NAS, new active substance.